摘要
目的探讨经纤维支气管镜支气管肺泡灌洗术(BAL)对肺癌患者24 h动脉血气分析指标与炎性因子水平的影响。方法选取2019年4月至2020年3月期间本院收治的共计69例肺癌患者,采用随机摸球法分为A组(n=35)和B组(n=34),A组采用经纤维支气管镜BAL治疗,B组采用常规对症治疗,比较两组24 h动脉血气分析指标、炎性因子水平及症状改善情况。结果两组治疗24 h后脉搏血氧饱度(SpO_(2))、动脉血氧分压(PaO_(2))水平明显提高(P<0.05),二氧化碳分压(PaCO_(2))水平明显降低(P<0.05),A组与B组相比SpO_(2)、PaO_(2)水平明显更高(P<0.05),PaCO_(2)水平明显更低(P<0.05);两组治疗后白介素-6(IL-6)、降钙素原(PCT)、肿瘤坏死因子-α(TNF-α)水平明显降低(P<0.05),A组与B组相比明显更低(P<0.05);A组与B组相比体温恢复正常、白细胞计数正常、咳痰消失时间明显更短(P<0.05)。结论肺癌患者应用经纤维支气管镜BAL治疗,能够有效改善24 h动脉血气分析指标,对改善临床症状及炎性因子水平的降低具有重要作用。
Objective To investigate the effect of bronchoalveolar lavage(BAL)via fiber bronchoscope on arterial blood gas and inflammatory factors in patients with lung cancer.Methods A total of 69 patients with lung cancer admitted to our hospital from April 2019 to March 2020 were divided into A group(N=35)and B group(N=34)by random touch ball method.group A was treated with BAL via fiber bronchoscope,and group B was treated with symptomatic treatment,arterial blood gas analysis,inflammatory factors and symptom improvement were compared between the two groups at 24 hours.Results After 24 hours of treatment,SpO_(2) and PaO_(2) in both groups were significantly increased(P<0.05),PaCO_(2) was significantly decreased(P<0.05),SpO_(2) and PaO_(2) in group A were significantly higher than those in group B(P<0.05),the level of PaCO_(2) was significantly lower(P<0.05),the levels of interleukin-6(IL-6),procalcitonin(PCT)and tumor necrosis factor(TNF-α)decreased significantly in both groups after treatment(P<0.05),and in group A was significantly lower than that in group B(P<0.05),the body temperature returned to normal,the white blood cell count was normal,and the expectoration time was significantly shorter(P<0.05).Conclusion BAL therapy through fiber bronchoscope can effectively improve the 24-hour arterial blood gas analysis index,which is important to improve clinical symptoms and reduce inflammatory factors.
作者
徐强
李志军
XU Qiang;LI Zhijun(Department of Respiratory and Critical Care Medicine,General Hospital of Hebi Coal Industry(Group)Co.Ltd,Hebi Henan 458000,China)
出处
《临床研究》
2022年第2期5-8,共4页
Clinical Research